Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com -- Shares of Maia Biotechnology Inc (NYSE American:MAIA) climbed 3.4% today after the company reported encouraging survival data from its THIO-101 pivotal Phase 2 clinical trial. The trial evaluated ateganosine, Maia’s lead clinical candidate, in combination with Regeneron (NASDAQ:REGN)’s cemiplimab for advanced non-small cell lung cancer (NSCLC) patients resistant to standard treatments.
The updated data, released on May 15, 2025, indicated a median overall survival (OS) of 17.8 months among the 22 NSCLC patients who received at least one dose of ateganosine. This figure is significantly higher than the 5 to 6 months OS typically observed with standard-of-care chemotherapy for similar patient populations. The treatment’s safety profile was also noted as generally well-tolerated among the heavily pre-treated patients.
MAIA’s Chairman and CEO Vlad Vitoc, M.D., expressed optimism regarding the results, stating, "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in medical literature." He added that the data could be an indicator of ateganosine’s potential to transform the NSCLC treatment paradigm.
The company also highlighted the possibility of accelerated FDA approval and robust exclusivity for ateganosine in the NSCLC market, with a potential decision from the FDA expected as early as next year. This news has likely contributed to the positive investor sentiment, as the stock’s upward movement reflects the market’s response to the trial’s promising outcomes and the prospect of regulatory advancements.
Investors and analysts will continue to watch MAIA closely as the company progresses towards potential FDA approval, which could mark a significant milestone in the treatment of NSCLC and potentially enhance the company’s market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.